Noncardiogenic pulmonary edema: An unusual and serious complication of anticancer therapy

Oncologist

Volumn 6, Issue 2, 2001, Pages 153-161

  Briasoulis, Evangelos ^a   Pavlidis, Nicholas ^a  

^a UNIVERSITY OF IOANNINA   (Greece)

Author keywords

Acute lung injury; All trans retinoic acid; ARDS; Arsenic trioxide (As2O3); Chemotherapy; Cytarabine; Gemcitabine; Interleukin 2; NCPE; Noncardiogenic pulmonary edema; Pulmonary toxicity

Indexed keywords

ANTINEOPLASTIC AGENT; ARSENIC TRIOXIDE; BLEOMYCIN; CORTICOSTEROID; CYTARABINE; DACARBAZINE; DIURETIC AGENT; DOCETAXEL; FOTEMUSTINE; GEMCITABINE; GRANULOCYTE COLONY STIMULATING FACTOR; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; INTERLEUKIN 2; METHOTREXATE; MITOMYCIN; NITROSOUREA DERIVATIVE; RECOMBINANT INTERLEUKIN 2; RETINOIC ACID; VINBLASTINE;

ARTICLE; ASSISTED VENTILATION; CLINICAL FEATURE; CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; DIURESIS; DRUG WITHDRAWAL; FLU LIKE SYNDROME; HUMAN; HYPOXEMIA; LUNG EDEMA; LUNG FIBROSIS; LUNG INFILTRATE; LUNG TOXICITY; PATHOGENESIS; PATHOPHYSIOLOGY; PNEUMONIA; PRIORITY JOURNAL; SYMPTOMATOLOGY; THORAX RADIOGRAPHY;

ANTINEOPLASTIC AGENTS; HUMANS; NEOPLASMS; PULMONARY EDEMA;

EID: 0035049505     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.6-2-153     Document Type: Article

References (105)

1. Pulmonary toxicity of antineoplastic therapy
2. Pulmonary toxicity
3. Fatal bleomycin pulmonary toxicity in the west of Scotland 1991-95: A review of patients with germ cell tumours
4. Active lung fibrosis up to 17 years after chemotherapy with carmustine (BCNU) in childhood
5. A prospective study of pulmonary function in patients receiving mitomycin
6. Nitrosourea derivatives-induced pulmonary toxicity in patients treated for malignant brain tumors. Early subclinical detection and its prevention
7. Bleomycin induced pulmonary toxicity
8. Chemotherapy induced noncardiogenic pulmonary edema: Case report related to gemcitabine plus docetaxel combination with G-CSF support
9. Pulmonary edema and acute lung injury
10. The American-European Consensus Conference on ARDS. Definitions, mechanisms, relevant outcomes, and clinical trial coordination
11. Drug-induced pulmonary disease. An update
12. Drug-induced pulmonary disease. Part 1: Cytotoxic drugs
13. Subacute pulmonary failure complicating therapy with high-dose Ara-C in acute leukemia
14. Drug-induced noncardiogenic pulmonary edema
15. Pulmonary complications of cytosine-arabinoside therapy: Radiographic findings
16. Systemic administration of interleukin-2 in humans
17. NIH conference. New approaches to the immunotherapy of cancer using interleukin-2
18. Recombinant interleukin-2-based treatments for advanced melanoma: The experience of the European Organization for Research and Treatment of Cancer Melanoma Cooperative Group
19. Interleukin-2-based therapy for metastatic renal cell cancer: The Cytokine Working Group experience, 1989-1997
20. Protracted venous infusion 5-fluorouracil in combination with subcutaneous interleukin-2 and alpha-interferon in patients with metastatic renal cell cancer: A phase II study
21. Durable complete responses in metastatic melanoma treated with interleukin-2 in combination with interferon alpha and chemotherapy
22. Effects of route and formulation on clinical pharmacokinetics of interleukin-2
23. Clinical toxicity of interleukin-2
24. High-dose continuous intravenous infusion of interleukin-2 therapy for metastatic renal cell carcinoma: The University of Chicago experience
25. Increase of rat pulmonary microvascular permeability to albumin by recombinant interleukin-2
26. Pathogenesis of pulmonary edema during interleukin-2 therapy: Correlation of chest radiographic and clinical findings in 54 patients
27. Pulmonary edema as a complication of interleukin-2 therapy
28. Clinical effects and toxicity of interleukin-2 in patients with cancer
29. Extravasation of intravascular fluid mediated by the systemic administration of recombinant interleukin 2
30. Cardiorespiratory effects of immunotherapy with interleukin-2
31. Vascular leak syndrome associated with interleukin-2: Chest radiographic manifestations
32. Trends in the safety of high dose bolus interleukin-2 administration in patients with metastatic cancer
33. Long-term subcutaneous recombinant interleukin-2 as maintenance therapy: Biological effects and clinical implications
34. Inhaled interleukin-2 therapy in pulmonary metastatic renal cell carcinoma: Six years of experience
35. Serious pulmonary complications in patients receiving recombinant granulocyte colony-stimulating factor during BACOP chemotherapy for aggressive non-Hodgkin's lymphoma
36. Pulmonary toxicity of ABVD chemotherapy and G-CSF in Hodgkin's disease: Possible synergy
37. Chemoradiotherapy with or without granulocyte-macrophage colony-stimulating factor in the treatment of limited-stage small-cell lung cancer: A prospective phase III randomized study of the Southwest Oncology Group
38. A risk of pulmonary edema associated with G-CSF pretreatment
39. Fatal G-CSF-induced pulmonary toxicity
40. Impairment in gas exchange after granulocyte colony stimulating factor (G-CSF) in a patient with the adult respiratory distress syndrome
41. GM-CSF therapy and capillary-leak syndrome
42. Capillary leak syndrome during low dose granulocyte-macrophage colony-stimulating factor (rh GM-CSF) treatment of a patient in a continuous febrile state
43. Capillary leak syndrome in a patient with septicemia and granulocyte-colony-stimulating factor (G-CSF)-induced accelerated granulopoiesis
44. G-CSF instillation into rat lungs mediates neutrophil recruitment, pulmonary edema, and hypoxia
45. Gemcitabine
46. Cytarabine
47. Fatal pulmonary failure complicating high-dose cytosine arabinoside therapy in acute leukemia
48. Pulmonary insufficiency complicating therapy with high dose cytosine arabinoside in five pediatric patients with relapsed acute myelogenous leukemia
49. Ara-C lung: Noncardiogenic pulmonary edema complicating cytosine arabinoside therapy of leukemia
50. Pulmonary edema and shock after high-dose aracytine-C for lymphoma; possible role of TNT-alpha and PAF
51. Gemcitabine - A safety review
52. Dyspnea with gemcitabine is commonly seen, often disease related, transient and rarely severe
53. A report on serious pulmonary toxicity associated with gemcitabine-based therapy (36th Annual Meeting)
54. Fatal pulmonary toxicity resulting from treatment with gemcitabine
55. Severe acute lung injury induced by gemcitabine
56. Sudden cardio-pulmonary toxicity following a single infusion of gemcitabine
57. Fatal pulmonary toxicity resulting from treatment with gemcitabine
58. Severe non-haematological toxicity after treatment with gemcitabine
59. Diffuse alveolar damage in a patient treated with gemcitabine
60. Successful treatment of gemcitabine toxicity with a brief course of oral corticosteroid therapy
61. Acute diffuse interstitial pneumopathy following docetaxel (Taxotere). Apropos of 2 cases
62. Docetaxel and interstitial pulmonary injury
63. Coping with toxicities of docetaxel (Taxotere)
64. Docetaxel in patients with metastatic breast cancer: A phase II study of the National Cancer Institute of Canada-Clinical Trials Group
65. Capillary protein leak syndrome appears to explain fluid retention in cancer patients who receive docetaxel treatment
66. Severe pulmonary toxicity in patients treated with a combination of docetaxel and gemcitabine for metastatic transitional cell carcinoma
67. Combined radiochemotherapy with docetaxel in patients with unresectable locally advanced head and neck tumors
68. Pulmonary edema associated with intravenous vinblastine
69. Vinblastine-associated pulmonary toxicity in patients receiving combination therapy with mitomycin and cisplatin
70. Possible pulmonary toxicity secondary to vinblastine
71. Fatal acute respiratory failure after vinblastine-mitomycin therapy in lung carcinoma
72. Pneumonitis complicating low-dose methotrexate therapy for rheumatoid arthritis. Discrepancies between lung biopsy and bronchoalveolar lavage findings
73. Noncardiogenic pulmonary edema following injection of methotrexate into the cerebrospinal fluid
74. Fatal acute respiratory failure following intrathecal methotrexate administration
75. Marrow engraftment and clinical manifestations of capillary leak syndrome
76. Pulmonary toxicity of induction chemotherapy prior to standard or high-dose chemotherapy with autologous hematopoietic support
77. A clinical and experimental study on all-trans retinoic acid-treated acute promyelocytic leukemia patients
78. BCR-ABL mediates arsenic trioxide-induced apoptosis independently of its aberrant kinase activity
79. Arsenic trioxide as an inducer of apoptosis and loss of PML/RAR alpha protein in acute promyelocytic leukemia cells
80. All-transretinoic acid in acute promyelocytic leukemia
81. Studies on treatment of acute promyelocytic leukemia with arsenic trioxide: Remission induction, follow-up, and molecular monitoring in 11 newly diagnosed and 47 relapsed acute promyelocytic leukemia patients
82. Incidence, clinical features, and outcome of all trans-retinoic acid syndrome in 413 cases of newly diagnosed acute promyelocytic leukemia. The European APL Group
83. Leukocytosis and the retinoic acid syndrome in patients with acute promyelocytic leukemia treated with arsenic trioxide
84. The "retinoic acid syndrome" in acute promyelocytic leukemia
85. Weekly gemcitabine in advanced or metastatic solid tumors. A clinical phase I study
86. Toxicity of high dose Ara-C in children and adolescents
87. Induction of tumor necrosis factor-α as a cause of bleomycin-related toxicity
88. Ara-C syndrome during low-dose continuous infusion therapy
89. The toxicity of cytarabine
90. Phase I study of gemcitabine using a once every 2 weeks schedule
91. Corticosteroids significantly delay the onset of docetaxel-induced fluid retention: Final results of a randomized study of the European Organization for Research and Treatment of Cancer Investigational Drug Branch for Breast Cancer
92. Tumor necrosis factor-alpha plays a central role in IL-2-induced pulmonary vascular leak and lymphocyte accumulation
93. Platelet activating factor mediates IL-2-induced lung injury in the rat
94. Morphological basis of pulmonary edema in mice with cytokine-induced vascular leak syndrome
95. IL-2-induced lung injury is mediated by oxygen free radicals
96. Activation of the complement system during immunotherapy of cancer with IL-2: A possible explanation of the capillary leak syndrome
97. Involvement of thromboxane and neutrophils in multiple-system organ edema with IL-2
98. Functional IL-2 receptors are expressed by rat lung type II epithelial cells
99. In vitro effect of granulocyte-colony stimulating factor and all-trans retinoic acid on the expression of inflammatory cytokines and adhesion molecules in acute promyelocytic leukemic cells
100. All-transretinoic acid induces simultaneously granulocytic differentiation and expression of inflammatory cytokines in HL-60 cells
101. Systemic capillary leak syndrome and monoclonal IgG gammopathy; studies in a sixth patient and a review of the literature
102. Systemic capillary leak syndrome with monoclonal IgG and complement alterations. A case report on an episodic syndrome
103. Ultrastructure of the microvessels in skeletal muscle in a case of systemic capillary leak syndrome
104. Noncardiogenic pulmonary edema complicating intermediate and high-dose Ara C treatment for relapsed acute leukemia
105. Activity and unexpected lung toxicity of the sequential administration of two alkylating agents - Dacarbazine and fotemustine - In patients with melanoma